Publications by the researcher in collaboration with José María Ruiz Moreno (19)

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

2022

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

  2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

    The Lancet, Vol. 399, Núm. 10326, pp. 741-755

2015

  1. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

  2. Patología retiniana en alta miopía

    Sociedad Española de Oftalmología (SEO)

  3. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

    Drugs and Aging, Vol. 32, Núm. 10, pp. 797-807

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014

2013

  1. Photodynamic therapy for chronic central serous chorioretinopathy: A 4-year follow-up study

    Retina, Vol. 33, Núm. 2, pp. 309-315

2012

  1. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization

    Acta Ophthalmologica

2011

  1. Myopic choroidal neovascularization

    Ophthalmology

2010

  1. Photodynamic therapy for chronic central serous chorioretinopathy

    Acta Ophthalmologica, Vol. 88, Núm. 3, pp. 371-376

  2. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization

    Retina, Vol. 30, Núm. 10, pp. 1609-1615

2009

  1. A 1-year retrospective review of ranibizumab for naïve nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration

    Retina, Vol. 29, Núm. 10, pp. 1444-1449

  2. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III

    European Journal of Ophthalmology, Vol. 19, Núm. 3, pp. 448-451

  3. Guías de práctica clínica de la SERV: Tratamiento de la degeneración macular asociada a la edad (DMAE) exudativa

    Archivos de la Sociedad Española de Oftalmologia, Vol. 84, Núm. 7, pp. 333-344

  4. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome

    British Journal of Ophthalmology, Vol. 93, Núm. 4, pp. 448-451

  5. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short-term results

    Eye, Vol. 23, Núm. 2, pp. 334-338

  6. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab

    British Journal of Ophthalmology

2006

  1. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization

    Acta Ophthalmologica Scandinavica, Vol. 84, Núm. 6, pp. 743-748